Science Translated, Hope Realized

What began as a scientific interest for D. Wade Clapp, MD, chair of the Department of Pediatrics at the Indiana University (IU) School of Medicine, has grown into a life-altering passion.

Dr. Clapp is a neonatologist who started in hematology, so pediatric sarcomas and genetic cancers are not his natural area of acumen. Yet, as he continued his research and began meeting patients and their families, the physician in him took over.

Dr. Clapp, who is focused on two rare genetic disorders called Neurofibromatosis type 1 (NF1) and Neurofibromatosis 2 (NF2), noted that almost a quarter million people ages 18 to 24 years old live with NF1 and 25,000 more individuals have NF2. However, NF2-linked tumors account for approximately 3 percent of all nervous system related tumors. Dr. Clapp and his colleagues have worked on NF1 for nearly 20 years and now have three drugs in clinical trials and one that is FDA approved. Their work in NF2 has begun much more recently.

NF2 is characterized by benign tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain, leading to deafness, vertigo, facial muscle weakness and chronic neuropathic pain.

“The primary way to treat NF2,” Dr. Clapp said recently, “hasn’t changed since I was in medical school. These kids, who live in our community, deserve more.” He went on to say, “Surgery carries significant risks, yet no long-term effective therapies exist for these highly debilitating tumors. This is why it’s so important to me to work to develop pharmaceutical approaches to halt or reverse the progression of tumor growth in patients.”

In Dr. Clapp's words

“The IBRI has tremendous chemistry expertise that opens us to novel compounds, drug combinations and chemical matter.”
–D. Wade Clapp, MD

Scientist in the lab
Bottles on a lab shelf

Dr. Clapp has worked with Steve Angus, PhD, assistant professor of pediatrics at the IU School of Medicine, to develop a series of genetically engineered mice with NF2 that develop tumors just like humans with NF2. These mice serve as vital surrogates, since there are so few young people living with NF2. Dr. Clapp and team have seen some initial successes with three potential drugs; however, it is his collaboration with the IBRI that will take his research to the next level.

In collaboration with the IBRI, Dr. Clapp and his colleagues are pursuing detailed screening combinations, with the goal of identifying drugs or drug combinations that could immediately proceed to Phase I/II clinical trials. “The IBRI offers us high-throughput screening capabilities and the ability to create induced pluripotent stem cells (iPSCs),” said Dr. Clapp. “Plus, the IBRI has tremendous chemistry expertise that opens us to novel compounds, drug combinations and chemical matter. We’re especially looking forward to the IBRI bringing its chemistry lab online in the fall.”

Dr. Clapp had been working with the IBRI’s Mary Mader, PhD, to explore PROTACs (proteolysis targeting chimera), which blocks both the activation of the kinase and inhibits its interaction with other proteins. For NF2 tumors, Dr. Clapp has been looking at a particular kinase that has the potential to suppress tumors.

Dr. Clapp and Mader are exploring the sensitivity of the kinase – taking it from micromolar to nanomolar. A kinase typically can inhibit the growth of a tumor but doesn’t kill it. “If we are able to use a kinase at such a low level with higher targeting, we might be able to kill the tumor,” said Dr. Clapp.

Navigate to the next section →

Read about our community connections